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Abstract
Atrial fibrillation is a frequent arrhythmia with increasing prevalence. The paper reviews the 
most important present aspects and paradigms in the treatment of the arrhythmia. The main 
aim of treatment is directed to improve the quality of life while reducing morbidity and mortal-
ity. A large experience derived from epidemiological registers and clinical research, impressive 
advances in interventional electrophysiological therapies and the introduction of non-vitamin 
K antagonists had a dramatic impact on the medical approach. Recommended steps to classify 
and treat atrial fibrillation are presented and discussed. (Cardiol J 2016; 23, 1: 3–11)
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Introduction
Atrial fibrillation (AF) is a common arrhyth-
mia. At present AF affects up to 2% of the general 
population [1] and in Europe has an estimated 
prevalence of 6 million. In United States, AF inci-
dence will double, from 1.2 million cases in 2010 to 
2.6 million cases in 2030 and given this increase in 
incidence, AF prevalence is projected to increase 
from 5.2 million in 2010 to 12.1 million cases in 
2030 [2]. Its frequency is augmenting due to the 
worldwide increasing patients’ age and contribut-
ing cardiovascular risk factors [2, 3]. Data on AF 
would fill a textbook. We review the most important 
recent aspects.
Diagnosis and risk stratification
The recommended steps to classify and treat 
AF (Table 1) are a) anamnesis and clinical findings, 
to diagnose whether AF is paroxysmal, persistent, 
long-standing (> 1 year), or permanent; b) a clinical 
and laboratory check-up; c) a 12-lead electrocardio-
gram (ECG); d) an echocardiographic assessment, 
and e) a long-term dynamic ECG [1, 3].
The main aim of treatment of AF is directed 
to increase the quality of life while reducing mor-
bidity and mortality. The degree of symptoms and 
co-existing pathologies are the basis for choosing 
the therapy. A large experience, derived from 
epidemiological registers and clinical research, 
impressive advances in interventional electro-
physiological therapies, and the introduction of 
non-vitamin K antagonists (NOAC) had a dramatic 
impact in the medical approach [4–7].
Thromboembolic prophylaxis
The reduction of thromboembolic complica-
tions is a capital aim of therapy. The CHA2-DS2- 
-VASc score (Table 2), developed when only vita-
min K antagonists (VKA) and antiplatelet agents 
were available [1, 3–5] and also used for NOAC 
has replaced previous scores and influences the 
thromboembolic prophylaxis in AF [5].
Antiplatelet agents
The use of aspirin, other antiplatelet agents, 
or their combination in the thromboembolic 
prophylaxis in AF is now generally not recom-
mended. The therapeutic effect is uncertain or 
insufficient and yet there is an increased bleeding 
risk [1, 3–7].
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Oral anticoagulation
Oral anticoagulation (OAC) is indicated with 
a CHA2-DS2-VASc score ≥ 2. The yearly stroke 
rate is related to the score as shown in Table 3. 
However, before using OAC it is necessary to 
consider general bleeding and safety profiles, and 
also possible interactions. It is recommended to 
use the HAS-BLED score (Table 4).
Vitamin K antagonists 
These drugs are loosely called VKA because 
they inhibit vitamin K epoxide reductase. Their 
Table 2. CHA2-DS2-VASc score.
Letter Explanation Points
C Congestive heart failure,  
also treated
1
H Hypertension, also treated 1
A2 Age > 75 years 2
D Diabetes mellitus, also treated) 1
S2 Stroke: transient ischemic  
attacks/stroke, cerebral stroke
2
V Vascular disease, also treated 1
A Age, 65–74 years 1
S Sex, female 1
≥ 2 points = indication for anticoagulation
Table 1. Recommended steps to classify and treat atrial fibrillation.
Diagnosis Therapy
General Anticoagulation
•	Symptoms (EHRA score) •	CHA2-DS2-VASc score
•	Clinical check-up •	Oral anticoagulation (VKA, NOAC)
•	Coexisting pathologies? Antiarrhythmic strategies
•	Laboratory •	Drugs controlling heart rate
Specific •	Sinus conversion if indicated and possible
•	12-lead ECG •	Catheter ablation when indicated
•	Echocardiography Treatment of co-morbidities
•	Long-term dynamic ECG •	Heart failure
•	Hypertension
•	Diabetes mellitus
•	Apnea/hypopnea
•	Respiratory pathology
•	Renal failure
•	Dyslipidemia
•	 Inflammatory pathology
ECG — electrocardiogram; NOAC — non-vitamin K antagonists; VKA — vitamin K antagonists
Table 3. Yearly cardio-embolic risk and  
CHA2-DS2-VASc score.
Score Yearly % risk
2 4
3 5
4 8.5
5 12.5
6 18.2
Table 4. HAS-BLED score.
Letter Explanation Points
H Hypertension, also treated 1
A Abnormal renal or liver function 
(1 point each)
1–2
S Stroke: transient ischemic  
attacks/stroke, cerebral stroke
1
B Bleeding 1
L Labile international normalized 
ratio (for VKA)
1
E Age > 65 years 1
D Drugs or alcohol (1 point each) 1–2
Maximum 9 points; VKA — vitamin K antagonists
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action may be antagonized by administration of 
vitamin K. In some countries non-coumarin VKA, 
especially 1,3-indandione derivatives (e.g., fluindi-
one and phenindione) are available. However, 4-hy-
droxycoumarins (coumarins), especially warfarin, 
are the commonly used VKA. Especially in some 
European countries, acenocoumarol and phenpro-
coumon are frequently used. VKA are still used, 
but the number of patients with AF who are first 
treated with NOAC or are switched from VKA to 
NOAC is steadily increasing. VKA are given with an 
individualized dosage in patients with AF to reach 
an international normalized ratio (INR) 2–3. It is 
noteworthy that to avoid the early prothrombotic 
state induced by VKA until a therapeutic INR is 
achieved [8] patients who are at high risk of cardio-
embolic events should receive a bridging therapy 
with low-molecular heparins in the early phase 
(4–5 days) of treatment, or should directly be 
treated with an NOAC (Table 5).
It should also be considered that OAC with 
VKA is problematic in patients with severe hepatic 
dysfunction: under this condition the validity of 
the prothrombin-time test and related tests for 
assessing the risk of hemorrhage and guiding OAC 
is strongly questioned [9] and this conditions may 
explain the problems related to the use of VKA in 
this pathology.
Vitamin K antagonists are highly effective in 
reducing thromboembolic complications in patients 
with AF [1, 3–7]. However, patients must take 
VKA throughout their lives and as with any other 
therapy there are also some ‘shadows’. It has been 
known since in the 1970s that women receiving 
VKA between the 6th and 12th week of pregnancy 
give birth to children with severe bone abnor-
malities. Recently it has been demonstrated that 
patients on coumarin-therapy develop cardiac val-
vular pathologies induced by basophilic-amorphous 
calcified deposits; it is hypothesized that treatment 
with coumarins induces incomplete g-carboxylation 
of the matrix-gla protein with a consequent de-
creased protection against tissue calcification 
[10]. Furthermore, more vitamin K is needed for 
carboxylation of bone production than for activation 
of clotting factor and concern has arisen that VKA 
could interfere with bone metabolism, putting pa-
tients at risk for osteoporosis. The impact of VKA 
Table 5. Relevant pharmacokinetics of acenocoumarol, phenprocoumon and warfarin.
Acenocoumarol Phenprocoumon Warfarin
Clot formation Yes* Yes* Yes*
Inhibition** The liver enzyme vit. K  
reductase (thus reduced  
form of vit. KH2)
The liver enzyme vit. K  
reductase (thus reduced  
form of vit. KH2)
The liver enzyme vit. K  
reductase (thus reduced  
form of vit. KH2)
Factors II, VII, IX, and X,  
ultimately reduced cleavage 
of fibrinogen into fibrin and 
decreased coagulability  
of the blood
Factors II, VII, IX, and X,  
ultimately reduced cleavage 
of fibrinogen into fibrin and 
decreased coagulability  
of the blood
Factors II, VII, IX, and X,  
ultimately reduced cleavage 
of fibrinogen into fibrin and 
decreased coagulability  
of the blood
Dose adjustment Individual Individual Individual
Activity*** Effects of genetic factors: 
unknown
Effects of genetic factors: 
unknown
Activity is determined  
partially by genetic factors
Patients older than 60 years 
and Asian patients appear to 
exhibit greater than expected 
INR response to the  
anticoagulant effects VKA
Patients older than 60 years 
and Asian patients appear to 
exhibit greater than expected 
INR response to the  
anticoagulant effects VKA
Patients older than 60 years 
and Asian patients appear to 
exhibit greater than expected 
INR response to the  
anticoagulant effects VKA
Half-life 8 ± 0.5 h 157 ± 12 h Mean 40 h (range 20–60 h)
Routine monitoring Mandatory, INR Mandatory, INR Mandatory, INR
Interactions Cytochrome P450:  
2C9 and 2C8
Cytochrome P450:  
2C9 and 2C8
CYP450: 2C9, 2C19, 2C8, 
2C18, 1A2, and 3A4
Vitamin K Vitamin K Vitamin K
 *When newly started, VKA may promote clot formation temporarily, because the level of protein C and protein S are also dependent on vit. K  
activity. For example, warfarin causes decline in protein C levels in first 36 h. In addition, reduced levels of protein S lead to a reduction in 
activity of protein C (for which it is the co-factor) and to a reduced degradation of factor Va and factor VIIIa. The hemostasis system becomes 
temporarily shifted towards thrombus formation, leading to a prothrombotic state; **Full doses of VKA produce a precipitous decline in factor 
VII, resulting in an initial prolongation of the INR. Full antithrombotic effect does not take place until significant reduction in factor II occurs  
(4–5 days later); ***Polymorphisms in two genes (VKORC1 and CYP2C9) play a particularly large role in response to warfarin. However, the 
clinical use of pharmacogenomic testing in warfarin dosing is controversial; INR — international normalized ratio; VKA — vitamin K antagonists
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in this setting is not well established, but there is 
evidence that these drugs have a negative effect 
on bone turnover [11].
Non-vitamin K antagonists
Non-vitamin K antagonists were mentioned 
in the 2010 guidelines of the European Society of 
Cardiology. In the 2015 guidelines, one finds 15 
suggestions about the use of NOAC in different 
scenarios. In our paper, we deal only with the use 
of NOAC in prevention of thromboembolic events 
in patients with AF. Large data from the use of 
NOAC have revolutionized and simplified OAC. At 
present available NOAC are dabigatran, apixaban, 
edoxaban and rivaroxaban. Their most impor-
tant pharmacokinetic data are shown in Table 6. 
The available data [5, 6] show that NOAC are 
equivalent and possibly better than VKA in the 
thromboembolic prophylaxis of patients with AF. 
Of note, compared to VKA, NOAC have a smaller 
risk for intracerebral bleeding [6, 7, 12, 13].
The mechanism of action of dabigatran dif-
fers from that of other available NOAC because it 
blocks directly and selectively thrombin. The most 
commonly reported side-effects of dabigatran are 
gastro-intestinal adverse-effects. When compared 
to people treated with VKA, patients taking da-
bigatran had fewer life-threatening bleeds, fewer 
minor and major bleeds, including intracranial 
bleeds, but the rate of gastro-intestinal bleeding 
was significantly higher. Dabigatran capsules con-
tain tartaric acid, which is required for adequate 
absorption and lowers the gastric pH. The lower 
pH has been associated with dyspepsia and it is 
hypothesized that this plays a role in the increased 
risk of gastrointestinal bleeding. A small but sig-
nificantly increased risk of acute coronary events 
has been noted when combining the safety outcome 
data from multiple trials [14].
Apixaban, edoxaban and rivaroxaban exert 
their anticoagulant effect via direct inhibition of 
a single factor (factor Xa). Major bleeding and fatal 
bleeding occurred significantly less frequently with 
these NOAC than with VKA, but gastro-intestinal 
and nasal bleeding is not rare [15–17]. It is hy-
pothesized that these side effects may be related 
to anticoagulatory active metabolites, which are 
absent in VKA. Rare side effects of edoxaban are 
abnormal liver function and rash [16]. Non-bleeding 
gastro-intestinal adverse effects of rivaroxaban 
(e.g. nausea) are very rare [17].
A recent interesting paper [17] with data col-
lected from countries with a reputed experience in 
the therapy with VKA shows that patients switched 
from VKA to NOAC have higher stroke risk pro-
files than patients directly treated with NOAC. 
Therefore, it seems possible that patients with AF 
who have been previously treated with VKA are 
different from those who have been untreated [18].
When using OAC it is important to consider 
the renal and to a certain extent the hepatic func-
tion. We have insufficient reports about the use of 
NOAC in patients with severe renal and/or hepatic 
dysfunction. It is proven, however, that a severe 
renal dysfunction (and also a severe hepatic dys-
function) may increase the bleeding risk, in NOAC 
mostly by inducing accumulation [12]. Research 
for specific antidotes for NOAC is ongoing, but 
Table 6. Pharmacokinetics of available non-vitamin K antagonists.
Dabigatran Apixaban Edoxaban Rivaroxaban
Inhibition Thrombin Factor Xa Factor Xa Factor Xa
Prodrug Yes No No No
Dose adjustment Related to age  
and eGFR
Related to age,  
eGFR and weight
Related to eGFR,  
co-medication  
and weight
Related to eGFR
Bioavailability 6% 70% 62% 80%
Protein binding 35% 90% 55% 90%
Dosage intervals bid bid oad oad
Half-life 12–14 h 12 h 8–10 h 7–11 h
Renal excretion 40% 25% 40% 35%
Routine monitoring No No No No
Interactions p-glycoprotein cytochrome P3A4  
and p-glycoprotein
cytochrome P3A4  
and p-glycoprotein
cytochrome P3A4  
and p-glycoprotein
eGFR — estimated glomerular filtration rate; bid — twice per day; oad — once per day
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specific antidotes are not yet available with few 
exceptions in hospital settings. Some patients were 
successfully treated with prothrombin concentrate 
complex.
Alternative thromboembolic prophylaxis 
when oral anticoagulation is contraindicated
Some patients with AF and high risk for throm-
boembolic complications cannot be safely treated 
with OAC because they also have an excessive 
bleeding risk or contraindicating co-morbidities. 
Thromboembolic events originate from the left 
atrium. Thus, in selected patients with AF in whom 
necessary OAC is contraindicated, left atrial ap-
pendage closure with an occluding device can be 
used [19–21]. The technique is quite effective in 
reducing thromboembolic events in AF [1, 3, 4, 
19–21], but several complications may occur [21]. 
For example, apixaban had to be used to treat 
protruding thrombus over left atrial appendage 
occlusion device [22].
Antiarrhythmic therapies
We have discussed the need for thromboem-
bolic prophylaxis but, of course treatment of the 
arrhythmia has also a central role. The therapy is 
adjusted to the symptoms and the duration of the 
AF, taking into proper account the co-morbidities. 
Possible therapeutic approaches are presented in 
Table 7.
Pharmacologic options
Table 8 shows antiarrhythmic drugs which 
may be used in the therapy AF. AF is a dynamic 
disease and altogether available antiarrhythmic 
drugs have a limited efficacy. Therefore, long-term 
antiarrhythmic treatment of AF is often less effec-
tive than required [3, 4, 23].
Heart rate control
In asymptomatic patients and, especially, in 
the elderly polymorbid patients with AF, heart rate 
control is often the 1st choice therapeutic option 
[3, 4, 23–25].
The use of digoxin is bond to a long-time 
debate. Especially in recent years, it is stated 
that, when used in patients with AF and manifest 
cardiac failure, digoxin increases the mortality 
[22–28]. Vamos et al. [28] suggest several poten-
tial mechanisms of digoxin-associated mortality 
increase: in many studies detected digoxin serum 
levels were higher (> 1.2 ng/mL) than the level 
now recommended; at toxic levels, digoxin may 
induces severe arrhythmias; digoxin has many 
interactions, e.g. with amiodarone and other anti-
arrhythmic drugs (and these drugs were used in 
the analyzed studies; digoxin increases vagal tone, 
reduces atrioventricular conduction and shortens 
atrial refractory periods, effects which may have 
pro-arrhythmic effects in AF; also, digoxin was 
found to be associated with doubling of relapses of 
Table 7. Antiarrhythmic therapy and/or rhythm control in atrial fibrillation.
Structurally normal heart
First line therapy
•	Flecainide
•	Propafenone
•	Sotalol
•	Dronedarone+
Second line therapy
•	Ablation
Known cardiac pathology
 Significant LVH CAD Cardiomyopathy Severe renal failure
First line therapy
•	Amiodarone •	Sotalol++ •	Amiodarone •	Amiodarone
•	Dronedarone+ •	Dofetilide
•	Dofetilide
Second line therapy
•	Amiodarone •	Amiodarone
•	Dofetilide
•	Ablation •	Ablation •	Ablation
+Dronedarone is contraindicated in patients with long-standing or permanent atrial fibrillation; ++Sotalol is contraindicated in the presence 
of severely impaired left ventricular function or severe renal failure; CAD — coronary artery disease; LVH — left ventricular hypertrophy
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AF following cardioversion. However, the statisti-
cally increased mortality in AF-patients treated 
with digoxin is open to debate [29–33]. Digoxin has 
been used for a long time, mostly in polymorbid 
patients, when other drugs have failed and there 
is no alternative pharmacologic treatment. It is 
well known that the therapeutic safety profile of 
digoxin is narrow, and overdose and/or an interac-
tion with antiarrhythmic drugs, diuretics etc. may 
induce toxic effects. Most recent studies describe 
dangerous electrophysiological effects which were 
described as digoxin-induced arrhythmias, but the 
serum levels were higher than safe, the electrolytic 
state (K+, Na+ etc.) were rarely reported: were the 
arrhythmias evidence for toxicity? Adverse-events 
due to improper use and toxicity should not be 
taken and evidence for increased mortality at low-
dose levels. Meta-analysis studies reporting effects 
and increased mortality of digoxin are difficult to 
be evaluated, because the use of digoxin and the 
treated patients cannot be properly compared [32, 
33]. Indeed, if properly titrated, taking into account 
digoxin pharmacokinetics and the co-morbidities 
(renal function, electrolytes) digoxin is effective in 
improving cardiac symptoms and (even not during 
physical exercise) it has a regulatory effect on heart 
rate. The impetus for novel methodologies regard-
ing analysis and reporting of results should not 
solely be driven by concerns of statistical power, 
but by a desire to better understand how therapies 
influence a broader characterization of total disease 
burden. Most disease progressions are associated 
with the realization of multiple complications and 
analysis may sometimes obfuscate the findings. 
Analysis of event arms may lend itself to conflict-
ing interpretations such as those presented in 
recent trials, there is the concern of type I error 
rate inflation due to multiple testing [34]. Thus, 
the reader is cautioned with this approach [34]. 
An exclusive focus on mortality may obscure 
important effects of medications [35]. Thus, the 
real effect of old digoxin on increased mortality 
(especially in polymorbid elderly patients) must be 
taken into consideration. Using two standardized 
Table 8. Antiarrhythmic drugs used in chronic therapy of atrial fibrillation.
Class Example Pro-arrhythmic  
potential
Other relevant  
adverse events
Contraindications
IC+ Flecainide and 
propafenone
Atrial flutter with 1:1 con-
duction++, VT/VF
Nausea, dyspepsia,  
paresthesia
CAD, LVH, long QT-time,  
LVD, HF NYHA IV
III Sotalol Torsades de pointes Bradycardia Severe LVD or severe RF
Dofetilide Torsades de pointes
Dronedarone++ Rare Decompensated HF,  
hepatic dysfunction (rare)
HF NYHA II with decom- 
pensation in the last weeks,  
long QT-time, previous SCD 
(with LVD, HF) permanent AF, 
relevant hepatic failure or RF
Amiodarone Rare Thyroid, lung, hepatic  
toxicity, optic neuropathy, 
polyneuropathy
Hepatic disease, interstitial 
lung disease
Digoxin Possible Dizziness, nausea, faint-
ing, pounding, or irregular 
heartbeat or pulse, brady-
cardia. Less common: black, 
tarry stools, bleeding gums, 
blood in the urine or stools, 
pinpoint red spots on the 
skin, rash with flat lesions or 
small raised lesions on the 
skin, stomach pain, unusual 
bleeding or bruising, gyne-
comastia, anxiety, confusion, 
impaired vision
Bradycardia, relevant RF  
or hepatic failure,  
electrolyte pathologies
Toxicity Proarrhythmic effect
+To counteract this pro-arrhythmic effect of IC class agents should be used in combination with drugs which reduces the AV-conduction  
(b-blocker, verapamil or diltiazem); ++Dronedarone is contraindicated in patients with long-standing or permanent atrial fibrillation (AF);  
CAD — coronary artery disease; HF — heart failure; LVD — left ventricular dysfunction; LVH — left ventricular hypertrophy; NYHA — New 
York Heart Association; RF — renal failure; SCD —  sudden cardiac death; VF — ventricular fibrillation; VT — ventricular tachycardia
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bias scoring systems, D. Kotecha (annual congress 
of the ESC in London 2015) has demonstrated that 
reviews reporting an association between mortality 
and digoxin were highly biased. No studies have 
evaluated the impact of digoxin in patients with AF 
without heart failure.The higher the observational 
study’s bias score, the greater the reported asso-
ciation between digoxin and mortality. In contrast, 
well conducted and randomized controlled trials all 
score a very low bias and carry a consistent mes-
sage that digoxin had a neutral effect on mortality. 
The best available evidence demonstrates that 
digoxin reduces hospital admission and has no ef-
fect upon all-cause mortality in patients with heart 
failure with or without atrial fibrillation.
Pharmacologic therapy aimed  
to restore/maintain sinus rhythm
First choice drugs are b-blockers or, when con-
traindicated, verapamil or diltiazem [3, 4, 23–26].
Asymptomatic patients and patients with im-
paired cardiac function often are effectively treated 
with a rhythm control strategy [1, 3, 22–25].
In patients with AF without structural car-
diac pathology antiarrhythmic agents of class IC 
(e.g., flecainide or propafenone), combined with 
a b-blocker, are the first choice [1]. In patients with 
relevant cardiac pathology, especially with an im-
paired left ventricular systolic function, amiodarone 
and dofetilide (class III antiarrhythmic drugs) are 
the first choice [1, 4, 25].
Amiodarone (class III agent) is the most effec-
tive therapeutic agent but, unfortunately its use is 
severely limited because of its many interactions 
and adverse effects; amiodarone should be used for 
a relatively short period [3, 4, 23–25].
Dronedarone (class III agent) should be used 
with many restrictions and is contraindicated in 
patients with heart failure and in those with per-
manent AF [4, 5, 23–25].
Vernakalant is a new antiarrhythmic drug that 
acts selectively in the atrium, targeting atrial specific 
channels: the Kv1.5 channel which carries IK (ur), 
and the Kir3.1/3.4 channel which carries IK (Ach): it 
can also work to block Ito, late Ina, and exert a minor 
blockade of IKr currents. Vernakalant is available in 
both intravenous and oral forms. Intravenous ver-
nakalant has been shown to be effective in termi-
nating acute onset AF whose duration is > 3 h and 
< 7 days (~50% efficacy vs. 10% for placebo). It does 
not appear to be effective for AF whose duration is 
> 7 days, nor does it appear to be effective for 
atrial flutter. Studies with oral vernakalant have 
been designed to evaluate its efficacy and safety in 
the prevention of AF recurrence. Up to date have 
the therapeutic efficacy was moderate; the most 
common side effects being dysgeusia, sneezing, 
paresthesia, nausea, and hypotension. In the clinical 
trials, there were minimal drug-induced ventricular 
arrhythmias observed.
Electrophysiological options  
to achieve sinus rhythm
The MAZE procedures were the first attempts 
to obtain and maintain sinus rhythm in AF [36]. 
A recent review [37] focuses on surgical options in 
the curative treatment of AF. Especially the hy-
brid approach, which combines the advantages of 
catheter and surgical ablation (with the excision or 
exclusion of the left atrial appendage), is a promis-
ing approach for the future. The knowledge about 
AF pathophysiology is steadily increasing and new 
data affect the therapeutic strategies. Because of 
the increased experience and good therapeutic re-
sults catheter-based ablation procedures (isolation 
of the pulmonary veins either by radiofrequency 
or cryoablation) have become a routine interven-
tion in cardiology and are increasingly used in AF. 
Indeed, the ablation therapy is becoming the 
1st choice therapy for symptomatic patients with AF 
[1, 4, 20, 36]. Patients’ preferences play without 
doubt a central role. The efficiency of the ablation is 
increasing. Nonetheless, the risk-advantage profile 
must be taken into account and some indications 
must be respected. The type and duration of AF, the 
type of cardiac disease, and the size and function of 
the atria must be considered to deliver a successful 
therapy. In centers with large numbers of interven-
tions complications occur in less than 4% of cases. 
Complications at the inguinal entrance occur in 
about 2% of cases. In less than 1% of cases cardiac 
tamponade may follow and require drainage. Tran-
sient ischemic complications or cerebral strokes 
occur in less than 1% of cases. Atrio-esophageal 
fistula is a feared complication, which occur in 
less than 0.2% of cases. Recent meta-analyses 
[3, 36] report that 77% of the ablation-treated 
patients are asymptomatic at a 1-year follow-up, in 
comparison to 52% of medically treated patients. 
It should be noted that up to a third of patients 
requires a 2nd ablation (redo-ablation) to achieve 
a long-lasting symptom-free life [3, 4, 23, 25, 38]. 
We still lack enough information to personalize 
ablation in each individual, which could results 
in more efficacious and less extensive ablation in 
some patients [39].
In some cases, pharmacologic treatment does 
not suffice to reduce sufficiently heart rate. In these 
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patients, an approach could be the interruption of 
the atrioventricular conduction by catheter abla-
tion and the implantation of a cardiac pacemaker 
[3]. This therapy has a 99% efficacy and has the 
advantage that many drugs to control the arrhyth-
mia can be discontinued.
Treatment of risk factors  
and co-morbidities
In recent years, the term ‘upstream therapy’ 
has been used to describe treatment of AF [3, 4, 
23–25]. It has been demonstrated that the effec-
tive treatment of cardiovascular risk factors (e.g., 
arterial hypertension, diabetes mellitus, tobacco 
consumption, sleep apnea/hypopnea, renal dysfunc-
tion, pulmonary diseases, inflammatory disorders, 
and dyslipidemia) has positive therapeutic effects 
on AF [3–7, 23–26]. A study [40] has shown that, 
in overweight patients with AF, a significant weight 
decrease, associated with a good control of meta-
bolic pathologies, reduces symptoms related to AF 
and also has a positive effect on cardiac remodeling. 
Among the drugs used to treat patients with AF it 
seems that angiotensin-converting enzyme inhibi-
tors/angiotensin-2 receptor antagonists, and statins 
(HMG CoA reductase inhibitors) are effective in 
slowing the evolution of AF. These drugs may 
reduce pathologic factors such as inflammation 
and fibrosis.
Lastly, it has been found that non-steroidal 
anti-inflammatory drugs increase the risk of AF [41] 
and it might be advisable, if possible, to use other 
analgesic drugs to treat patients at risk for AF.
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